

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
22 February 2018 (22.02.2018)



(10) International Publication Number  
**WO 2018/033815 A1**

- (51) **International Patent Classification:**  
*C07D 471/04* (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**  
PCT/IB2017/054655
- (22) **International Filing Date:**  
31 July 2017 (31.07.2017)

- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
62/371,602 15 August 2016 (15.08.2016) US  
62/533,347 17 July 2017 (17.07.2017) US

- (71) **Applicant:** PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

- (72) **Inventors:** BEHENNA, Douglas Carl; 31302 Calle Del Campo, San Juan Capistrano, CA 92675 (US). CHEN, Ping; 7666 Pipit Place, San Diego, CA 92129 (US). FREEMAN-COOK, Kevin Daniel; 7946 Sitio Nispero, Carlsbad, CA 92009 (US). HOFFMAN, Robert Louis; 2390 Rising Glen Way, #201, Carlsbad, CA 92008 (US). JALALE, Mehran; 11373 Saddle Cove Lane, San Diego, CA 92130 (US). NAGATA, Asako; 7335 Rock Canyon Drive, San Diego, CA 92126 (US). NAIR, Sajiv Krishnan; 1923 White Birch Drive, Vista, CA 92081 (US). NINKOVIC, Sacha; 8902 Nottingham Place, La Jolla, CA 92037 (US). ORNELAS, Martha Alicia; 15062 Avenida Montuose, Apartment C, San Diego, CA 92129 (US). PALMER, Cynthia Louise; 9847 Ogram Drive, La Mesa, CA 91941 (US). RUI, Eugene Yuanjin; 11254 Caminito Corriente, San Diego, CA 92128 (US).

- (74) **Agent:** WALDRON, Roy F.; Pfizer INC., 235 East 42nd Street, MS 235/9/S20, New York, NY 10017 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

- (54) **Title:** PYRIDOPYRIMIDINONE CDK2/4/6 INHIBITORS

- (57) **Abstract:** This invention relates to compounds of general Formula (I), and pharmaceutically acceptable salts thereof, in which  $R^1$ ,  $R^2$ ,  $R^{2A}$ ,  $R^{2B}$ ,  $R^3$ ,  $R^4$ ,  $R^{5A}$ ,  $R^{5B}$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ , p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.



WO 2018/033815 A1